SpIntellx’s pilot study predicts tumor risk recurrence
Contact Our Team
For more information about how Halldale can add value to your marketing and promotional campaigns or to discuss event exhibitor and sponsorship opportunities, contact our team to find out more
The Americas -
holly.foster@halldale.com
Rest of World -
jeremy@halldale.com
SpIntellx Inc. presented a poster at the American Association of Cancer Research (AACR) Annual Meeting on April 1, 2019, that demonstrates predictions of the risk of relapse in a pilot study of colon cancer over five years. SpIntellx is a computational and systems pathology company applying its proprietary explainable artificial intelligence (xAI) technologies to develop computational tools based on spatial analytics and systems biology for both transmitted light (HistoMaprTM) and fluorescence imaging pathology (TumorMaprTM) applications. The company is developing the TumorMapr platform to enable tailored therapeutic strategies optimizing individual outcomes by probing the spatial modulation of cancer biology in the tumor microenvironment (TME).
Colorectal cancer is the third most common cancer in men andthe second in women across all regions of the world, with approximately 1.3 millionnewly diagnosed cases every year, the company states. While the five-yearsurvival rates largely correlate with disease stages, adjuvant therapydecisions and treatment response predictions for at least one-third of newcases of colon cancer comprising mainly of stage II and III patients remainscontroversial.
A patient cohort of N = 432, distributed over stages I, II andIII from hyperplexed (55 fluorescence biomarkers) formalin-fixed andparaffin-embedded (FFPE) tissue samples (AUC= 0.885 ± 0.03) was used in thispilot study.
